With recent disruptive pricing in the HCV market, will lower cost therapies take share from legacy treatments? Preview what payers forecast back in the second half of 2016 with our M Tracker data.
With the evolution of payer management in different specialty classes, MKO has been tracking management priority and budget impact using our M Tracker. M Tracker has revealed a significant change in oncology and HCV management in the first half of 2017.
From the effects of Donald Trump’s election as US president to pioneering therapies for Alzheimer’s, some trends are set to continue and others to emerge as the global pharmaceutical industry pushes into 2017.
Medical 3D printing is making quick leaps and bounds and could soon be such a key integrated part of the medical world that we will wonder how we ever lived without it.
Patients in England could have faster access to effective cancer treatments through the reincarnated Cancer Drugs Fund (CDF), the National Institute for Health and Care Excellence (NICE) has announced.
Nearly one million people are diagnosed with cancer in the United States per year, according to The American Cancer Society, and although cancer therapeutics are among the most active areas in drug development, treatment still falls short of meeting patients’ needs.
The British pharmaceutical industry is facing new challenges following the UK’s decision to leave the European Union, a white paper has revealed. Published by Global Data, it warned of wide-reaching impacts.
3D printing has been making waves since 1984 when its inventor, Charles Hull, used the technology to make a 3D model from a picture, demonstrating that this technology would be a revolutionary way to test a product design before sinking big money into a large manufacturing program.
